Shareholders appear to hang onto Haemonetics, expecting it t...

Shareholders appear to hang onto Haemonetics, expecting it to keep beating market trends, due to its projected solid growth. Despite a high P/E, the predicted limited risk of an earnings drop keeps the share price stable.